West Pharmaceutical Services Inc (WST) SEC filings

WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3032% above fair value

$416.42+5.12 (+1.24%)

Close on Nov 13, 2026Market cap $29.01BP/E 46.7Yield 0.21%

SEC filings

40 of West Pharmaceutical Services's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 23, 2026	SEC EDGAR
Current report	8-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	8-K	Jul 14, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	May 31, 2026	Jun 1, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 5, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 4, 2026	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 17, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Oct 23, 2025	SEC EDGAR
Current report	8-K	Oct 23, 2025	Oct 23, 2025	SEC EDGAR
Current report	8-K	Sep 11, 2025	Sep 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 24, 2025	SEC EDGAR
Current report	8-K	Jul 24, 2025	Jul 24, 2025	SEC EDGAR
Current report	8-K	Jul 21, 2025	Jul 21, 2025	SEC EDGAR
Current report	8-K	May 6, 2025	May 8, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	Apr 24, 2025	SEC EDGAR
Current report	8-K	Apr 22, 2025	Apr 24, 2025	SEC EDGAR
Current report	8-K	Apr 24, 2025	Apr 24, 2025	SEC EDGAR
Current report	8-K	Apr 9, 2025	Apr 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 6, 2025	Mar 21, 2025	SEC EDGAR
Current report	8-K	Mar 7, 2025	Mar 11, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 18, 2025	SEC EDGAR
Current report	8-K	Feb 13, 2025	Feb 13, 2025	SEC EDGAR
Current report	8-K	Dec 9, 2024	Dec 13, 2024	SEC EDGAR
Current report	8-K	Dec 9, 2024	Dec 11, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Oct 24, 2024	SEC EDGAR
Current report	8-K	Oct 24, 2024	Oct 24, 2024	SEC EDGAR
Current report	8-K	Oct 1, 2024	Oct 7, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Jul 25, 2024	SEC EDGAR
Current report	8-K	Jul 25, 2024	Jul 25, 2024	SEC EDGAR
Current report	8-K	Jul 2, 2024	Jul 8, 2024	SEC EDGAR
Current report	8-K	Apr 23, 2024	Apr 26, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	Apr 25, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in West Pharmaceutical Services's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Sep 27, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is WST.

Compare: WST vs STVN · WST vs TFX · WST vs MMSI · WST vs GMED · WST vs PODD

Revenue growth12.6% · median 17.1%

Gross margin37.6% · median 63.7%

Operating margin23.0% · median 16.0%

Net margin18.8% · median 13.5%

Company	Revenue	Growth
WST	$3.40B	+12.6%
PODD	$3.19B	+26.5%
GMED	$3.14B	+13.4%
TFX	$2.26B	+20.9%
MMSI	$1.61B	+9.1%
STVN	–	–

Company

Next earnings (est.): Feb 11, 2027, before open
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 10,800
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 105770

Advertisement
300 × 250

See a number that looks wrong?